Go Pro
OTCMKTS:CURLF

Curaleaf Q4 2024 Earnings Report

Curaleaf logo
$9.47 -0.20 (-2.07%)
As of 08/14/2026 03:56 PM Eastern

Curaleaf EPS Results

Actual EPS
$0.06
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

Curaleaf Revenue Results

Actual Revenue
$331.05 million
Expected Revenue
$331.87 million
Beat/Miss
Missed by -$820.00 thousand
YoY Revenue Growth
N/A

Curaleaf Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Curaleaf Earnings Headlines

Your 10X AI demo is starting…
Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investment of 17 million dollars. He is known for predicting the 2020 market crash with striking accuracy. Today he is hosting a free live demo of his newest AI-driven trading approach, showing how he analyzes market data without guesswork or speculation.tc pixel
See More Curaleaf Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Curaleaf? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Curaleaf and other key companies, straight to your email.

About Curaleaf

Curaleaf (OTCMKTS:CURLF) is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates. The company also offers proprietary CBD wellness products designed to address pain relief, stress management and sleep support. Curaleaf’s dispensaries provide personalized consultation services, allowing both medical patients and adult-use consumers to select products best suited to their needs. In addition, Curaleaf supplies wholesale products to other licensed retailers in states where it holds cultivation and processing licenses.

Founded in 2010, Curaleaf has expanded through strategic acquisitions, including the 2019 purchase of Grassroots Cannabis and the 2020 acquisition of Select, a premium U.S. cannabis oil brand. These transactions have broadened the company’s geographic footprint and product capabilities. Under the leadership of CEO Matt Darin, Curaleaf continues to pursue disciplined growth, regulatory compliance and innovation in cannabinoid research to support its long-term vision of becoming the most trusted brand in global cannabis.

View Curaleaf Profile